Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals4.24%-0.80 ppLife Sciences Tools & Services1.01%-0.64 ppManaged Health Care1.28%-0.59 ppHealth Care Equipment2.70%-0.22 ppBiotechnology2.07%-0.21 ppHealth Care Services0.55%-0.13 ppHealth Care Supplies0.11%-0.08 ppHealth Care Facilities0.21%-0.03 ppHealth Care Technology0.03%+0.03 ppHealth Care Distributors0.45%+0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.07%
Industry change · 12M
-0.21 pp
Biotechnology · contribution
-0.207 pp
Company participation
50%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Apr 2025 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals → REGN | United States | $56.3bn | 0.135% | -0.006 pp | -0.107 pp | -32.7% | No |
| Moderna → MRNA | United States | $11.0bn | 0.026% | -0.007 pp | -0.096 pp | -74.1% | No |
| Gilead Sciences → GILD | United States | $132.7bn | 0.319% | +0.049 pp | +0.083 pp | +69.5% | Yes |
| Amgen → AMGN | United States | $156.3bn | 0.375% | +0.034 pp | -0.050 pp | +9.4% | Yes |
| Biogen → BIIB | United States | $17.7bn | 0.043% | -0.004 pp | -0.048 pp | -43.6% | No |
| Vertex Pharmaceuticals → VRTX | United States | $130.8bn | 0.314% | +0.050 pp | +0.020 pp | +29.7% | Yes |
| AbbVie → ABBV | United States | $344.4bn | 0.827% | +0.104 pp | -0.005 pp | +24.3% | Yes |
| Incyte → INCY | United States | $12.1bn | 0.029% | -0.003 pp | -0.005 pp | +20.4% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.